MiNK Therapeutics, Inc. (INKT)

NASDAQ: INKT · IEX Real-Time Price · USD
3.17 -0.19 (-5.65%)
Jan 14, 2022 4:00 PM EST - Market closed
Market Cap106.21M
Revenue (ttm)n/a
Net Income (ttm)-17.76M
Shares Out33.50M
EPS (ttm)-0.53
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume271,220
Open3.22
Previous Close3.36
Day's Range3.07 - 3.45
52-Week Range3.07 - 22.16
Betan/a
AnalystsStrong Buy
Price Target26.67 (+741.3%)
Earnings Daten/a

About INKT

MiNK Therapeutics is a clinical stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (NK) cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of t...

IndustryBiotechnology
IPO DateOct 15, 2021
CEOJennifer S. Buell, Ph.D.
Employees34
Stock ExchangeNASDAQ
Ticker SymbolINKT
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for INKT stock is "Strong Buy." The 12-month stock price forecast is 26.67, which is an increase of 741.32% from the latest price.

Price Target
$26.67
(741.32% upside)
Analyst Consensus: Strong Buy

News

MiNK Therapeutics to Participate at Upcoming B. Riley Securities Virtual Oncology Conference

NEW YORK, Jan. 12, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invar...

3 days ago - GlobeNewsWire

MiNK Therapeutics to Participate in 4th Annual Evercore ISI HealthCONx Conference

NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invar...

1 month ago - GlobeNewsWire

MiNK Therapeutics Announces 77% Survival Rate in Intubated Patients with COVID-19 Respiratory Failure Treated with Ag...

NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invar...

2 months ago - GlobeNewsWire

MiNK Therapeutics Announces Closing of Initial Public Offering

NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invar...

2 months ago - GlobeNewsWire

MiNK Therapeutics, Inc. Announces Pricing of Initial Public Offering

NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (“MiNK”), a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-s...

3 months ago - GlobeNewsWire